NDA for bexarotene capsules submitted June 23 for second-line treatment of early-stage cutaneous T-cell lymphoma, refractory or persistent early CTCL and refractory late-stage CTCL. Ligand, which already markets Ontak (denileukin diftitox) for CTCL, requested a priority review for the orphan indication
You may also be interested in...
Amnesteem Cannot Claim “Esteem,” FDA Tells Mylan In Letter On Acne Drug
FDA is citing Mylan for claims on Amesteem's website that the acne product can address problems with low self-esteem
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011